Lisata Therapeutics (NASDAQ:LSTA – Get Rating) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its peers? We will compare Lisata Therapeutics to related companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, analyst recommendations and earnings.
Earnings & Valuation
This table compares Lisata Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Lisata Therapeutics||N/A||-$27.47 million||-0.32|
|Lisata Therapeutics Competitors||$2.97 billion||$132.19 million||9.55|
Lisata Therapeutics’ peers have higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Insider & Institutional Ownership
15.6% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 23.9% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Lisata Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Lisata Therapeutics Competitors||-2,169.68%||-130.61%||-26.39%|
This is a summary of current ratings for Lisata Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Lisata Therapeutics Competitors||32||246||370||30||2.59|
Lisata Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 279.75%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 85.55%. Given Lisata Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Lisata Therapeutics is more favorable than its peers.
Lisata Therapeutics peers beat Lisata Therapeutics on 8 of the 13 factors compared.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.